,0
symbol,AKRO
price,29.0
beta,0.0
volAvg,178093
mktCap,1006323200
lastDiv,0.0
range,10.78-41.16
changes,0.23
companyName,Akero Therapeutics Inc
currency,USD
cik,0001744659
isin,US00973Y1082
cusip,00973Y108
exchange,NasdaqGS
exchangeShortName,NASDAQ
industry,Biotechnology
website,https://www.akerotx.com/
description,"Akero Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 10 full-time employees. The firm is engaged in nonalcoholic steatohepatitis (NASH), a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease, or NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. The Companyâ€™s lead product candidate, AKR-001, which the Company is developing as a treatment for patients with NASH, is an analog of fibroblast growth factor 21 (FGF21). FGF21 is an endogenously-expressed hormone that regulates metabolism of lipids, carbohydrates and proteins throughout the body."
ceo,Dr. Andrew Cheng
sector,Healthcare
country,US
fullTimeEmployees,13
phone,16504876488
address,170 Harbor Way
city,South San Francisco
state,CALIFORNIA
zip,94080
dcfDiff,
dcf,30.0989
image,https://financialmodelingprep.com/image-stock/AKRO.png
ipoDate,2019-06-20
defaultImage,False
